Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
Dexamethasone (HB2521)
Description:Anti-inflammatory synthetic glucocorticoid. Induces hMSC differentiation. Apoptosis inducer.
Purity:>98%
Dexamethasone (water-soluble) (HB6020)
Description:Synthetic glucocorticoid with potent anti-inflammatory actions. Induces hMSC differentiation. Apoptosis inducer. Water soluble and suitable for cell culture.Â
Purity:>98%
FK 506 (HB0289)
Description:Potent calcineurin phosphatase 2B inhibitor. Enhances osteoblastic differentiation in mesenchymal cells.
Purity:>99%
FTY720 hydrochloride (HB3899)
Description:Sphingosine 1-phosphate (S1P) receptor (S1P1, S1P3, S1P4, and S1P5) modulator
Purity:>98%
Mycophenolic acid (HB3987)
Description:Inosine monophosphatase dehydrogenase inhibitor
Purity:>98%
Rapamycin (HB2779)
Description:mTOR inhibitor and potent immunosuppressant. Also used in inducible gene editing methods (e.g. CRISPR/Cas9) and promotes hPSC differentiation.
Purity:>98%
6-Thioguanine (HB1379)
Description:Competitive hypoxanthine-guanine phosphoribosyltransferase substrate
Purity:>99%